BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28810293)

  • 21. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
    Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
    J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of decalcification agents on immunoreactivity of cellular antigens.
    Athanasou NA; Quinn J; Heryet A; Woods CG; McGee JO
    J Clin Pathol; 1987 Aug; 40(8):874-8. PubMed ID: 2443541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of immunohistochemistry HER2 results interpretation in invasive micropapillary carcinoma of the breast].
    Yang W; Wei B; Chen M; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2015 Jan; 44(1):48-52. PubMed ID: 25765031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation.
    Bossuyt V; Fadare O; Martel M; Ocal IT; Burtness B; Moinfar F; Leibl S; Tavassoli FA
    Int J Surg Pathol; 2005 Oct; 13(4):319-27. PubMed ID: 16273187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology.
    Kurbel S; Dmitrović B; Marjanović K; Vrbanec D; Juretić A
    BMC Cancer; 2017 Mar; 17(1):231. PubMed ID: 28356061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of histological decalcifying agents on number and stainability of gram-positive bacteria.
    Wijnbergen M; Van Mullem PJ
    J Dent Res; 1987 May; 66(5):1029-31. PubMed ID: 2440925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of different decalcifying agents on EGF and EGFR immunostaining.
    Neves Jdos S; Omar NF; Narvaes EA; Gomes JR; Novaes PD
    Acta Histochem; 2011 Jul; 113(4):484-8. PubMed ID: 20598354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
    Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of decalcifying agents on the staining of Mycobacterium tuberculosis.
    Anderson G; Coup AJ
    J Clin Pathol; 1975 Sep; 28(9):744-5. PubMed ID: 51859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Auto-analysis of immunohistochemical findings for breast cancer using specified software and virtual microscopy].
    Tanaka M; Kuraoka K; Sakane J; Kodama Y; Nishimura T; Tanaka M; Tatsushima J; Saitou A; Taniyama K
    Rinsho Byori; 2012 Mar; 60(3):206-11. PubMed ID: 22568082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a fully automated HER2 staining kit in breast cancer.
    Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
    Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
    Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.